Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Dako's Genetic Test for Breast Cancer Recurrence

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved a genetic test made by Dako Denmark designed to predict if a breast cancer tumor will recur and a patient’s chances of long-term survival, the FDA said yesterday.
 
The TOP2A FISH pharmDx test uses fluorescent in situ hybridization to detect or to confirm abnormalities in the topoisomerase 2 alpha gene, which is involved in DNA replication. Changes in this gene in breast cancer cells can be used to predict likelihood of tumor recurrence or long-term survival of a patient. The FDA said the TOP2A FISH pharmDx is the first test to be approved that targets the TOP2A gene in cancer patients.
 
The FDA has deemed the test suitable for premenopausal patients or those who have other indicators of higher chances of tumor recurrence, such as tumor size or lymph node involvement, or decreased survival.
 
The test was studied in Danish patients who were treated with chemotherapy after removal of breast cancer tumors. That study used data from tumor samples and clinical data from 767 patients with high-risk tumors, and it confirmed that the test was useful in estimating recurrence and survival in women who had received chemotherapy, said the FDA.
 
Dako received the CE mark for the test last summer and has since launched the assay in Europe. A Dako spokesperson said that the firm expects to launch the test in the US in April or May.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.